Therapeutic Options for CRAB

Launched by CLINICAL HOSPITAL CENTRE ZAGREB · May 27, 2024

Keywords

ClinConnect Summary

This clinical trial is studying how to better treat infections caused by a type of bacteria called CRAB, which is known for being resistant to many antibiotics. These infections often occur in patients in intensive care units (ICUs) and can lead to serious health problems. The trial aims to find the best combinations of existing treatments to improve patient outcomes, such as reducing infection severity and increasing survival rates. Researchers will compare different treatment combinations to see which works best for patients who have tested positive for CRAB and have signs of serious infection.

To be eligible for this trial, participants must be adults over 18 years old who have had surgery and are receiving care in the ICU. They should have a positive test showing they have a CRAB infection. However, individuals with allergies to the study medications or those without signs of infection will not be included. Participants can expect close monitoring and care as part of the trial, and the study will help improve future treatment options for CRAB infections.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Surgical patients (abdominal, vascular, and polytraumatized patients)
• • Older than 18 years
• • Require postoperative treatment in the ICU
• • A positive sample (surveillance or diagnostic) for A. baumannii with signs of systemic infection
• • Infection will be defined as a diagnostic microbiologically positive sample for A. baumannii and a surveillance microbiologically positive sample for A. baumannii with signs of systemic infection (elevated CRP, leukocytes, and body temperature).
• • Colonization will be defined as a positive surveillance microbiological sample for A. baumannii in the absence of signs of systemic infection (normal CRP, leukocytes, and body temperature).
• Exclusion Criteria:
• • Allergy to the study medications
• • Positive surveillance swabs for A. baumannii without signs of systemic infection
• • Positive findings (surveillance or diagnostic) for carbapenem-sensitive A. baumannii
• • Refusal to participate in the research